Clal Biotechnology traded at 81.30 this Thursday June 30th, decreasing 1.10 or 1.34 percent since the previous trading session. Looking back, over the last four weeks, Clal Biotechnology lost 11.82 percent. Over the last 12 months, its price fell by 60.91 percent. Looking ahead, we forecast Clal Biotechnology to be priced at 79.99 by the end of this quarter and at 73.43 in one year, according to Trading Economics global macro models projections and analysts expectations.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Peers Price Day Year
Clal Biotechnology 81.30 -1.10 -1.34% -60.91%
Compugen 617.50 0.70 0.11% -76.43%

Indexes Price Day Year
TA-125 1884 -42.29 -2.20% 6.70%

Clal Biotechnology
Clal Biotechnology Industries Ltd (CBI) is an Israel-based biotechnology investment company. CBI's investments are targeted at bio-pharmaceutical companies, which are at different stages of research and development. The Company is a 59%-owned subsidiary of Clal Industries and Investments Ltd. (CII) that is part of IDB group. Clal Biotechnology Industries Ltd. has a number of portfolio companies, namely Andromeda Biotech Ltd., engaged in the field of type 1 diabetes; D-Pharm Ltd and Trombutech, engaged in the field of ischemic stroke; Mediwound Ltd., engaged in burn and wound management; Biokine Ltd, Biocancell Ltd and CureTech, engaged in the field of cancer; Braintact, engaged in the CNS field and Polyheal Ltd, engaged in wound management, among others.